Evaluation of renal function when using dexamethasone therapy in Patients with Covid-19 in Najaf City

Main Article Content

Hanan Diekan Abbas
Ahmed Hassan Kudhair

Keywords

renal physiology, dexamethasone, COVID-19, renal abnormalities, glomerular filtration rate

Abstract

Background: The COVID-19 is the one of the most reason that induce the renal problems and could even attack so many organs that might ends with increase the mortality and morbidity rate in the worldwide. One of its common cases is the chronic renal impairment that may be worse and increase the death rate in complete impair renal function. On the other hand the treatment or restoring of the renal abnormality could be occurred in hospital monitoring with a steroid treatment. A regular steroid intake with assessment of renal function base on a urea, creatinine and glucose levels is a good road path to improve the renal function and so shorten the time required for the patient to stay in the hospital.
Aim: to predict if the steroid treatment (dexamethasone) could improve the renal function and facilitate the curing rate of the patients.
Materials and Method: a case control study was conducted from sixty individuals, one half take the dexamethasone and suffer from COVID with the renal impairment and the other thirty patient was also have the COVID and renal abnormality but without this steroid drug, the blood sample and serum glucose, creatinine and urea measurement was performed.
Results: data showed that the level of urea, creatinine and glucose concentrations is lower in those COVID patient with renal abnormalities and take a steroid treatment compared to those didn’t take the course of this drug.
Conclusion: steroid treatment is one of the drugs that might improve the case of the patient and might participate in faster the curing rate of the patient and resorting the renal function to the normal level.

Abstract 261 | pdf Downloads 86

References

1. Noreen S, Maqbool I, Madni A. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. European journal of pharmacology. 2021; 894: 173854.
2. Group TRC. Dexamethasone in hospitalized patients with Covid-19-preliminary report. The New England journal of medicine. 2020.
3. Lammers T, Sofias AM, Van der Meel R, Schiffelers R, Storm G, Tacke F, et al. Dexamethasone Nanomedicine for COVID-19. Nature nanotechnology. 2020; 15(8): 622-4.
4. Theoharides T, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020; 34(3): 1241-3.
5. Group RC. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine. 2021; 384(8):693-704.
6. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. Jama. 2020; 324(13): 1292-5.
7. Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN comprehensive clinical medicine. 2020; 2(12): 2637-46.
8. Johnson RM, Vinetz JM. Dexamethasone in the management of covid-19. British Medical Journal Publishing Group. 2020.
9. Lester M, Sahin A, Pasyar A. The use of dexamethasone in the treatment of COVID-19. Annals of Medicine and Surgery. 2020; 56: 218.
10. Faour WH, Choaib A, Issa E, Choueiry FE, Shbaklo K, Alhajj M, et al. Mechanisms of COVID-19-induced kidney injury and current
pharmacotherapies. Inflammation Research. 2021: 1-18.
11. Bruchfeld A. The COVID-19 pandemic: consequences for nephrology. Nature Reviews Nephrology. 2021; 17(2): 81-2.
12. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET, 14 States, March 1-30, 2020. MMWR. Morbidity and Mortality Weekly Report. 69 (15): 458-464.
13. Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, et al. Characteristics of SARS-CoV-2 patients dying in Italy Report based on available data on July 22nd, 2020 (PDF) (Report). Istituto Superiore di Sanità. 2020.
14. Berton A, Prencipe N, Giordano R, Ghigo E, Grottoli S. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view. J Endocrinol Invest. 2021; 44(4): 873–875., doi: 10.1007/s40618-020-01325-2
15. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomised controlled trial. Lancet Respir Med. 2020; 8: 267–276, doi: 10.1016/S2213-2600(19)30417-5.
16. Hasan SS, Capstick T, Ahmed R, Kow CS, Mazhar F, Merchant HA, Zaidi STR. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expet Rev. Respir. Med. 2020; 14(11): 1149–1163